News
News Center
2019-08-26
The reform measures explicitly state: Medical institutions in Beijing are encouraged to initiate cutting-edge clinical research projects on stem cell technologies, based on their respective technical capabilities and in accordance with relevant national regulations. (Deadline: By the end of December 2019; Responsible units: Municipal Health Commission, Municipal Science and Technology Commission)
+
2019-08-26
Stroke Forum: Who Will Achieve the First Breakthrough in Stem Cell Therapy for Stroke?
For 20 consecutive years, stroke has been the leading cause of death and disability among Chinese residents. Today, the incidence of stroke continues to rise, with an alarming trend toward younger ages at onset. May the light of regenerative medicine shine brightly on the lives of China's 12.42 million stroke survivors living with long-term disabilities—we’re committed to making this vision a reality!
+
2019-08-22
How close are stem-cell therapies for ischemic stroke to reaching the market?
Every new drug is born much like Xuanzang's quest for the scriptures—after years of perseverance and enduring eighty-one tribulations, it finally achieves its ultimate purpose, thanks to unwavering determination and resilience. This holds especially true for stem-cell therapies.
+
2019-08-21
What precautions should be taken when undergoing stem cell therapy? After undergoing hematopoietic stem cell bone marrow transplantation, will the DNA of the transplanted individual’s blood match that of the recipient? Can mesenchymal stem cells be produced in bulk?
+
2019-08-20
In 2018, Jiuzhitang turned its focus toward the cutting-edge international field of bio-cellular technology by establishing Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. As the sole Chinese partner for stem cell technologies developed by the U.S.-based company Stemedica, the company began pursuing business opportunities related to stem cell research. Meanwhile, Jiuzhitang signed a "Joint Construction Agreement for a Stem Cell Clinical Research Base" with Beijing Tiantan Hospital, Affiliated to Capital Medical University, jointly establishing the "Jiuzhitang Maker Stem Cell Clinical Research Base at Beijing Tiantan Hospital," which has now been completed.
+
2019-08-14
On August 13, the Shanghai Municipal Government Information Office held a press conference, where Vice Mayor Xu Kunlin introduced the newly released "Several Measures for Further Opening Up Shanghai's Service Sector." Attendees included Hua Yuan, Director of the Municipal Commission of Commerce; Zhu Min, Deputy Director of the Municipal Development and Reform Commission; Cheng Meihong, Deputy Director of the Municipal Bureau of Culture and Tourism; and Peng Wenhao, Deputy Director of the Municipal Administration for Market Regulation, who jointly answered questions from reporters.
+
2019-07-31
Recently, the official website of the Hainan Provincial Health Commission published "Reply from the Hainan Provincial Health Commission to Proposal No. 0391 of the Second Session of the Seventh Committee of the Hainan Provincial Committee of the Chinese People's Political Consultative Conference (Response Category: B)." The reply clearly states that, in the area of cutting-edge medical technology research, to standardize and promote clinical research and translational applications of biomedical frontier technologies in the pilot zone, the Provincial Health Commission has drafted the "Provisional Measures for the Access, Clinical Research, and Translational Application Management of Stem Cell Medical Technologies in the Pilot Zone," which will be officially issued soon.
+
2019-07-30
Jiuzhitang is making strides in the stem-cell field, with promising prospects for future growth.
As a national key Chinese medicine enterprise, a national key high-tech enterprise, a national pilot innovative company, and the leading enterprise in Hunan Province’s pharmaceutical industry, Jiuzhitang boasts a rich historical legacy, a strong brand image, and significant industry influence. Now, with its strategic expansion into the stem-cell field, we believe that Jiuzhitang’s future growth prospects are indeed promising.
+
2019-07-29
Stem cell therapy shows immense potential for treating liver cirrhosis and liver failure.
To honor the discoverer of the hepatitis B virus—late Nobel laureate Baruch Blumberg—July 28 has been designated as World Hepatitis Day.
+
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy